Clinical Trial Update: Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for Philadelphia chromosome–positive CML patients with suboptimal response or tolerance to Bcr-Abl TKIs.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelogenous Leukemia

Snippet

Sponsor: Il-Yang Pharm. Co., Ltd. | Conditions: Leukemia, Leukemia, Myeloid | Phase 1, Phase 2 | Status: COMPLETED